Free Trial

Boston Scientific (BSX) Stock Price, News & Analysis

Boston Scientific logo
$102.96 +0.55 (+0.54%)
Closing price 03:57 PM Eastern
Extended Trading
$102.98 +0.02 (+0.02%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Boston Scientific Stock (NYSE:BSX)

Key Stats

Today's Range
$101.60
$103.21
50-Day Range
$98.43
$107.45
52-Week Range
$71.88
$107.53
Volume
6.24 million shs
Average Volume
6.67 million shs
Market Capitalization
$152.32 billion
P/E Ratio
75.15
Dividend Yield
N/A
Price Target
$116.09
Consensus Rating
Buy

Company Overview

Boston Scientific Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

BSX MarketRank™: 

Boston Scientific scored higher than 93% of companies evaluated by MarketBeat, and ranked 81st out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Boston Scientific has received a consensus rating of Buy. The company's average rating score is 3.13, and is based on 21 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Boston Scientific has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Boston Scientific's stock forecast and price target.
  • Earnings Growth

    Earnings for Boston Scientific are expected to grow by 13.33% in the coming year, from $2.85 to $3.23 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Boston Scientific is 75.15, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.93.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Boston Scientific is 75.15, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.58.

  • Price to Earnings Growth Ratio

    Boston Scientific has a PEG Ratio of 2.70. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Boston Scientific has a P/B Ratio of 6.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Boston Scientific's valuation and earnings.
  • Percentage of Shares Shorted

    1.19% of the float of Boston Scientific has been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 2.76%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Boston Scientific does not currently pay a dividend.

  • Dividend Growth

    Boston Scientific does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.19% of the float of Boston Scientific has been sold short.
  • Short Interest Ratio / Days to Cover

    Boston Scientific has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Boston Scientific has recently increased by 2.76%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Boston Scientific has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 63 news articles for Boston Scientific this week, compared to 29 articles on an average week.
  • Search Interest

    39 people have searched for BSX on MarketBeat in the last 30 days. This is an increase of 30% compared to the previous 30 days.
  • MarketBeat Follows

    22 people have added Boston Scientific to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Boston Scientific insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $47,755,193.00 in company stock.

  • Percentage Held by Insiders

    Only 0.50% of the stock of Boston Scientific is held by insiders.

  • Percentage Held by Institutions

    89.07% of the stock of Boston Scientific is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Boston Scientific's insider trading history.
Receive BSX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Boston Scientific and its competitors with MarketBeat's FREE daily newsletter.

BSX Stock News Headlines

Banks aren’t ready for this altcoin—are you?
I've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. This is about being in the right place at the right time – and I believe that time is now.
See More Headlines

BSX Stock Analysis - Frequently Asked Questions

Boston Scientific's stock was trading at $89.32 on January 1st, 2025. Since then, BSX stock has increased by 15.3% and is now trading at $102.96.

Boston Scientific Corporation (NYSE:BSX) issued its quarterly earnings results on Wednesday, April, 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The company's revenue was up 20.9% compared to the same quarter last year.
Read the conference call transcript
.

Boston Scientific subsidiaries include VertiFlex, BTG, Augmenix, Veniti, Claret Medical, Cryterion Medical, nVision Medical, and more.

Top institutional shareholders of Boston Scientific include E. Ohman J or Asset Management AB (0.03%), Czech National Bank (0.02%), Gradient Investments LLC (0.01%) and Legacy Wealth Management LLC MS. Insiders that own company stock include Michael F Mahoney, Daniel J Brennan, Joseph Michael Fitzgerald, Vance R Brown, Jonathan Monson, Eric Francis Yves Thepaut, Wendy Carruthers, Jeffrey B Mirviss, Nelda J Connors, Edward J Ludwig, Edward J Ludwig, Arthur C Butcher, John Bradley Sorenson and Charles J Dockendorff.
View institutional ownership trends
.

Shares of BSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Boston Scientific investors own include BlackRock (BLK), Broadcom (AVGO), ServiceNow (NOW), UnitedHealth Group (UNH), The Goldman Sachs Group (GS), NVIDIA (NVDA) and Illinois Tool Works (ITW).

Company Calendar

Last Earnings
4/23/2025
Today
7/09/2025
Next Earnings (Estimated)
7/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Health Care Equipment
Current Symbol
NYSE:BSX
CIK
885725
Employees
53,000
Year Founded
1979

Price Target and Rating

High Price Target
$130.00
Low Price Target
$100.00
Potential Upside/Downside
+12.7%
Consensus Rating
Buy
Rating Score (0-4)
3.13
Research Coverage
24 Analysts

Profitability

Trailing P/E Ratio
75.15
Forward P/E Ratio
36.13
P/E Growth
2.7
Net Income
$1.85 billion
Pretax Margin
14.12%

Debt

Sales & Book Value

Annual Sales
$17.55 billion
Cash Flow
$3.62 per share
Price / Cash Flow
28.44
Book Value
$14.93 per share
Price / Book
6.90

Miscellaneous

Outstanding Shares
1,479,446,000
Free Float
1,472,049,000
Market Cap
$152.32 billion
Optionable
Optionable
Beta
0.68

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NYSE:BSX) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners